Journal
BRITISH JOURNAL OF CANCER
Volume 125, Issue 2, Pages 152-154Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-021-01342-9
Keywords
-
Categories
Funding
- National Institutes of Health [NIH CA84356, NIH R21CA13508]
- Imugene Ltd
Ask authors/readers for more resources
Developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) with ethics approvals for Phase 1 clinical trial in Australia and Investigational New Drug approval by US FDA for Imugene Ltd testing in NSCLC. Demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available